BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
$9,94
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 5, 2026
52W-Spanne
$6–$11
75% of range
Analystenbewertung
BUY
17 analysts
Kursziel
$21
+109% upside
P/E (TTM)
9.8
ROE
-97.6%
Nettogewinnmarge
30.2%
Über BioCryst Pharmaceuticals, Inc. - Common Stock Unternehmensübersicht von Wikipedia
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
Mehr lesen
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
BCRX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$9.94
Marktkapitalisierung
$2.52B
P/E (TTM)
9.8
EPS (TTM)
$1.21
Umsatz (TTM)
$875M
Dividendenrendite
—
ROE
-97.6%
Verschuldungsgrad
0.0
52W-Spanne
$6 – $11
BCRX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$875M
2016-12-31
→
2025-12-31
EPS
$1.21
2020-12-31
→
2025-12-31
Freier Cashflow
$345M
2016-12-31
→
2025-12-31
Margen
30.2%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
BCRX
Peer-Median
P/E (TTM)
9.8
97.6
P/S (TTM) (K/V (TTM))
2.9
7.7
P/B (K/B)
-21.2
8.0
EV / EBITDA
6.6
—
Price / FCF (Kurs / FCF)
7.3
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
BCRX
Peer-Median
Operating Margin (Betriebsgewinnmarge)
39.0%
—
Net Profit Margin (Nettogewinnmarge)
30.2%
-51.7%
ROA
52.5%
-44.2%
ROE
-97.6%
-63.5%
ROIC
-282.4%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
BCRX
Peer-Median
Debt / Equity (Fremdkapital / Eigenkapital)
0.0
18.7
Current Ratio (Liquiditätsgrad)
2.1
4.9
Quick Ratio
1.9
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
BCRX
Peer-Median
Revenue YoY (Umsatz YoY)
94.1%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
47.8%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
117.9%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
BCRX
Peer-Median
BCRX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
17 Analysten
- Starker Kauf 5 29,4%
- Kauf 10 58,8%
- Halten 2 11,8%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
11 Analysten · 2026-08-17
Median
$17.00
Mittelwert
$20.82
← Unter allen Zielen
$9.94
Tief
$12.00
Hoch
$32.00
Median-Ziel
$17.00
+71,0%
Mittelwert-Ziel
$20.82
+109,4%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.02%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $0.30 | $0.12 | 0.18% |
| 31. März 2026 | $-0.09 | $0.05 | -0.14% |
| 31. Dezember 2025 | $0.01 | $0.04 | -0.03% |
| 30. September 2025 | $0.06 | $0.04 | 0.02% |
| 30. Juni 2025 | $0.04 | $0.01 | 0.03% |
| 31. März 2025 | $0.00 | $-0.07 | 0.07% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | — |
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| COAG | — | — | — | — | — | — |
| MLYS | $2.96B | -15.8 | — | — | -32.2% | — |
| KLRA | — | — | — | — | — | — |
| VERA | — | -10.9 | — | — | -55.9% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
Bilanz 27
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
Cashflow 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
Liquidität & Solvenz 5
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 13
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | -418,684,000 | 210,176,000 | 209,519,000 | 208,882,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | -436,451,000 | 219,885,000 | 219,886,000 | 215,261,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
Bilanz 24
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
Cashflow 14
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
Liquidität & Solvenz 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
Effizienz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
Bewertung (TTM) 13
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $697M | $625M | · | $585M | $535M | $465M | · | $406M | $371M | $331M | · | $314M | $293M | $260M | · | $232M | |
| Net Income TTM | $-625M | $-704M | · | $4M | $-22M | $-62M | · | $-98M | $-160M | $-200M | · | $-207M | $-230M | $-229M | · | $-234M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -3.8 | -3.3 | · | 759.0 | -81.5 | -25.0 | · | -15.5 | -7.5 | -4.9 | · | -6.4 | -5.7 | -6.8 | · | -9.8 | |
| P/S | 3.7 | 3.9 | · | 2.7 | 3.5 | 3.4 | · | 3.9 | 3.4 | 3.2 | · | 4.3 | 4.6 | 6.1 | · | 10.1 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| P / FCF | · | -38.9 | · | · | · | -56.7 | · | · | · | -19.4 | · | · | · | -33.0 | · | · | |
| EV / EBITDA | 26.4 | -3.7 | · | 53.4 | 62.6 | 73.7 | · | 232.9 | 172.6 | -89.7 | · | -125.1 | -71.5 | -59.0 | · | -133.3 | |
| EV / FCF | · | -41.4 | · | · | · | -57.5 | · | · | · | -23.6 | · | · | · | -34.7 | · | · | |
| EV / Revenue | 3.7 | 4.1 | · | 2.7 | 3.5 | 3.4 | · | 4.4 | 4.1 | 3.8 | · | 4.8 | 5.1 | 6.4 | · | 10.0 | |
| Earnings Yield | -26.0% | -30.5% | · | 0.13% | -1.2% | -4.0% | · | -6.5% | -13.3% | -20.5% | · | -15.5% | -17.5% | -14.8% | · | -10.2% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $875M | $451M | $331M | $271M | $157M |
| Betriebsgewinnmarge % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| Nettoergebnis | $264M | $-89M | $-227M | $-247M | $-184M |
| Verwässerte EPS | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| Liquiditätsgrad | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $345M | $-53M | $-97M | $-163M | $-145M |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 346 Einreicher · $2.1B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 63 (-7 vs. Vorquartal) | 34 (-7 vs. Vorquartal) | 130 (+19 vs. Vorquartal) | 83 (+3 vs. Vorquartal) | +25.9M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $158.271.860 | 15.827.186 | 7,51% | Aktien |
| STATE STREET CORP | $151.910.980 | 15.191.098 | 7,21% | Aktien |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150.964.030 | 15.096.403 | 7,16% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $113.642.360 | 11.364.236 | 5,39% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111.391.580 | 11.139.158 | 5,29% | Aktien |
| TCG Crossover Management, LLC | $110.209.680 | 11.020.968 | 5,23% | Aktien |
| PERCEPTIVE ADVISORS LLC | $103.088.880 | 10.308.888 | 4,89% | Aktien |
| JANUS HENDERSON GROUP PLC | $83.961.589 | 8.814.865 | 3,98% | Aktien |
| Vestal Point Capital, LP | $83.000.000 | 8.300.000 | 3,94% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $67.753.490 | 6.775.349 | 3,21% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $53.581.572 | 5.356.880 | 2,54% | Aktien |
| Aberdeen Group plc | $53.108.710 | 5.310.871 | 2,52% | Aktien |
| Frazier Life Sciences Management, L.P. | $40.092.400 | 4.009.240 | 1,90% | Aktien |
| GOLDMAN SACHS GROUP INC | $35.393.210 | 3.539.321 | 1,68% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $33.947.290 | 3.394.729 | 1,61% | Aktien |
| TWO SIGMA ADVISERS, LP | $31.895.074 | 4.089.112 | 1,51% | Aktien |
| RP Management, LLC | $28.846.155 | 3.846.154 | 1,37% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $27.161.110 | 2.716.111 | 1,29% | Aktien |
| Fisher Asset Management, LLC | $26.040.270 | 2.604.027 | 1,24% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $25.302.900 | 2.530.290 | 1,20% | Aktien |
| Kynam Capital Management, LP | $25.226.600 | 2.522.660 | 1,20% | Aktien |
| Candriam S.C.A. | $25.125.293 | 2.514.949 | 1,19% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23.532.910 | 2.353.291 | 1,12% | Aktien |
| RICE HALL JAMES & ASSOCIATES, LLC | $23.320.430 | 2.332.043 | 1,11% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $21.850.110 | 2.185.011 | 1,04% | Aktien |
| Nantahala Capital Management, LLC | $19.011.600 | 1.901.160 | 0,90% | Aktien |
| Eversept Partners, LP | $18.656.530 | 1.865.653 | 0,89% | Aktien |
| ORBIMED ADVISORS LLC | $18.520.000 | 1.852.000 | 0,88% | Aktien |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18.449.120 | 1.844.912 | 0,88% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $17.595.730 | 1.759.573 | 0,83% | Aktien |
| CITADEL ADVISORS LLC | $17.591.600 | 1.759.160 | 0,83% | Aktien |
| IMC-Chicago, LLC | $16.343.360 | 1.634.336 | 0,78% | Aktien |
| Parkman Healthcare Partners LLC | $16.242.790 | 1.624.279 | 0,77% | Aktien |
| JANE STREET GROUP, LLC | $14.267.680 | 1.426.768 | 0,68% | Aktien |
| OP Asset Management Ltd | $13.409.900 | 1.340.990 | 0,64% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.956.510 | 1.195.651 | 0,57% | Aktien |
| Pictet Asset Management Holding SA | $11.951.392 | 1.249.771 | 0,57% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $11.740.520 | 1.174.052 | 0,56% | Aktien |
| FIRST TRUST ADVISORS LP | $11.204.690 | 1.120.469 | 0,53% | Aktien |
| JANE STREET GROUP, LLC | $9.944.130 | 994.413 | 0,47% | Kaufoption |
| Cubist Systematic Strategies, LLC | $9.462.419 | 1.246.696 | 0,45% | Aktien |
| MOORE CAPITAL MANAGEMENT, LP | $8.483.360 | 848.336 | 0,40% | Aktien |
| FMR LLC | $8.062.330 | 806.233 | 0,38% | Aktien |
| BANK OF AMERICA CORP /DE/ | $7.754.020 | 775.402 | 0,37% | Aktien |
| ExodusPoint Capital Management, LP | $7.449.170 | 744.917 | 0,35% | Aktien |
| Man Group plc | $7.324.800 | 732.480 | 0,35% | Aktien |
| Rosalind Advisors, Inc. | $7.215.040 | 721.504 | 0,34% | Aktien |
| Schonfeld Strategic Advisors LLC | $7.108.160 | 710.816 | 0,34% | Aktien |
| BlackRock, Inc. | $5.984.400 | 598.440 | 0,28% | Aktien |
| Elmind Capital, LP | $5.200.000 | 520.000 | 0,25% | Aktien |
| Bridgewater Associates, LP | $4.910.570 | 491.057 | 0,23% | Aktien |
| NAN FUNG TRINITY (HK) LTD | $4.500.000 | 450.000 | 0,21% | Aktien |
| SPHERA FUNDS MANAGEMENT LTD. | $4.220.510 | 422.051 | 0,20% | Aktien |
| Swiss National Bank | $4.152.680 | 415.268 | 0,20% | Aktien |
| Susquehanna Portfolio Strategies, LLC | $4.047.040 | 404.704 | 0,19% | Aktien |
| DAFNA Capital Management LLC | $4.002.480 | 400.248 | 0,19% | Aktien |
| Hudson Bay Capital Management LP | $4.000.000 | 400.000 | 0,19% | Aktien |
| Aquatic Capital Management LLC | $3.628.950 | 362.895 | 0,17% | Aktien |
| DOLIVER CAPITAL ADVISORS, INC. | $3.563.603 | 374.328 | 0,17% | Aktien |
| Assenagon Asset Management S.A. | $3.530.440 | 353.044 | 0,17% | Aktien |
| Kodai Capital Management LP | $3.515.993 | 468.799 | 0,17% | Aktien |
| MACKENZIE FINANCIAL CORP | $3.472.990 | 347.299 | 0,16% | Aktien |
| CITIGROUP INC | $3.467.520 | 346.752 | 0,16% | Aktien |
| Phocas Financial Corp. | $3.405.410 | 340.541 | 0,16% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.238.000 | 323.800 | 0,15% | Kaufoption |
| ALPS ADVISORS INC | $3.179.600 | 317.960 | 0,15% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $3.121.694 | 327.909 | 0,15% | Aktien |
| RHUMBLINE ADVISERS | $2.798.390 | 279.839 | 0,13% | Aktien |
| Rafferty Asset Management, LLC | $2.656.180 | 265.618 | 0,13% | Aktien |
| Point72 Asset Management, L.P. | $2.609.170 | 260.917 | 0,12% | Aktien |
| Nuveen, LLC | $2.599.030 | 259.903 | 0,12% | Aktien |
| NFJ INVESTMENT GROUP, LLC | $2.568.330 | 256.833 | 0,12% | Aktien |
| Nebula Research & Development LLC | $2.567.121 | 286.509 | 0,12% | Aktien |
| WINTON GROUP Ltd | $2.556.000 | 255.600 | 0,12% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2.459.444 | 258.345 | 0,12% | Aktien |
| MARTINGALE ASSET MANAGEMENT L P | $2.425.080 | 242.508 | 0,12% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $2.324.670 | 232.467 | 0,11% | Aktien |
| CITADEL ADVISORS LLC | $2.322.000 | 232.200 | 0,11% | Kaufoption |
| IEQ CAPITAL, LLC | $2.274.210 | 227.421 | 0,11% | Aktien |
| Bank of New York Mellon Corp | $2.251.670 | 225.167 | 0,11% | Aktien |
| D. E. Shaw & Co., Inc. | $2.249.120 | 224.912 | 0,11% | Aktien |
| JUPITER ASSET MANAGEMENT LTD | $2.221.030 | 222.103 | 0,11% | Aktien |
| HUSSMAN STRATEGIC ADVISORS, INC. | $2.100.000 | 210.000 | 0,10% | Aktien |
| PFM Health Sciences, LP | $2.073.570 | 207.357 | 0,10% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.962.800 | 196.280 | 0,09% | Aktien |
| TUDOR INVESTMENT CORP ET AL | $1.951.280 | 195.128 | 0,09% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.853.000 | 185.300 | 0,09% | Verkaufsoption |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $1.820.161 | 233.354 | 0,09% | Aktien |
| Engineers Gate Manager LP | $1.750.020 | 175.002 | 0,08% | Aktien |
| Squarepoint Ops LLC | $1.747.140 | 174.714 | 0,08% | Aktien |
| QTR Family Wealth, LLC | $1.610.820 | 161.082 | 0,08% | Aktien |
| Gotham Asset Management, LLC | $1.564.210 | 156.421 | 0,07% | Aktien |
| CITADEL ADVISORS LLC | $1.450.000 | 145.000 | 0,07% | Verkaufsoption |
| Corient Private Wealth LP | $1.429.860 | 142.986 | 0,07% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $1.386.570 | 138.657 | 0,07% | Aktien |
| Quantinno Capital Management LP | $1.374.530 | 137.453 | 0,07% | Aktien |
| MetLife Investment Management, LLC | $1.356.700 | 135.670 | 0,06% | Aktien |
| PROFUND ADVISORS LLC | $1.340.340 | 134.034 | 0,06% | Aktien |
| Virtus Investment Advisers, LLC | $1.336.640 | 133.664 | 0,06% | Aktien |
| ADAR1 Capital Management, LLC | $1.330.000 | 133.000 | 0,06% | Aktien |
Unternehmensinsider 51 Insider · 21 Führungskräfte · 30 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17. Dezember 2025 A | 268.700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19. Dezember 2024 A | 377.867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21. Februar 2020 A | 125.176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16. März 2011 M | 57.102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22. Dezember 2025 M | 952.583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14. März 2008 A | 65.730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13. Mai 2026 M | 400.703 | 0 | 7 | $-3.461.969 |
| Sandeep Menon | Chief R&D Officer | 6. April 2026 A | 205.150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31. März 2025 F | 377.318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19. Dezember 2022 A | 16.653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14. November 2022 M | 298.541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10. März 2022 M | 37.954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15. Dezember 2020 A | 45.000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28. Januar 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15. März 2012 F | 24.124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 7. Februar 2011 A | 9.766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12. März 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31. Juli 2008 P | 3.048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31. Juli 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31. Juli 2007 P | 3.659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16. Mai 2007 A | 1.928 | 0 | 0 | $0 |
| Amy E Mckee | Direktor | 11. Juni 2026 A | 47.177 | 0 | 1 | $-100.285 |
| Theresa Heggie | Direktor | 11. Juni 2026 A | 80.646 | 0 | 1 | $-504.823 |
| Machelle Sanders | Direktor | 11. Juni 2026 A | 45.936 | 0 | 1 | $-68.544 |
| Jill C. Milne | Direktor | 11. Juni 2026 A | 31.938 | 0 | 0 | $0 |
| Steven Frank | Direktor | 11. Juni 2026 A | 35.459 | 0 | 0 | $0 |
| Steven K Galson | Direktor | 11. Juni 2026 A | 27.794 | 0 | 0 | $0 |
| Jon P Stonehouse | Direktor | 11. Juni 2026 A | 1.339.775 | 0 | 0 | $0 |
| Vincent Milano | Direktor | 11. Juni 2026 A | 108.483 | 0 | 0 | $0 |
| Alan G Levin | Direktor | 11. Juni 2026 A | 79.565 | 0 | 0 | $0 |
| Nancy J Hutson | Direktor | 12. Juni 2025 A | 99.138 | 0 | 0 | $0 |
| George B Abercrombie | Direktor | 12. Juni 2024 A | 36.431 | 0 | 0 | $0 |
| Steve Aselage | Direktor | 12. Juni 2024 A | 70.159 | 0 | 0 | $0 |
| Kenneth B Lee JR | Direktor | 13. Juni 2023 A | 68.863 | 0 | 0 | $0 |
| Robert Alexander Ingram | Direktor | 28. Februar 2023 A | 100.198 | 0 | 0 | $0 |
| Stanley C Erck | Direktor | 28. November 2018 M | 48.333 | 0 | 0 | $0 |
| Fred Cohen | Direktor | 20. Juni 2018 A | 119.410 | 0 | 0 | $0 |
| Sanj K Patel | Direktor | 24. Mai 2017 A | — | 0 | 0 | $0 |
| Charles A Sanders | Direktor | 29. Februar 2016 A | 12.971 | 0 | 0 | $0 |
| Peder Jensen | Direktor | 2. Mai 2014 A | 60.000 | 0 | 0 | $0 |
| John L Higgins | Direktor | 23. Mai 2012 A | — | 0 | 0 | $0 |
| HOROVITZ ZOLA P | Direktor | 23. Mai 2012 A | 3.000 | 0 | 0 | $0 |
| Stephen R Biggar | Direktor | 12. Mai 2011 A | — | 0 | 0 | $0 |
| Beth C Seidenberg | Direktor | 13. Mai 2010 A | 3.000 | 0 | 0 | $0 |
| William W Featheringill | Direktor | 13. Mai 2010 A | 231.538 | 0 | 0 | $0 |
| William M Spencer III | Direktor | 16. Mai 2007 A | 186.761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | Direktor | 16. Mai 2007 A | 451.900 | 0 | 0 | $0 |
| Charles E Bugg | Direktor | 18. März 2007 A | 62.439 | 0 | 0 | $0 |
| GORDON CARL L | Direktor | 17. Mai 2006 A | 1.100.000 | 0 | 0 | $0 |
| John A Montgomery | Direktor | 4. November 2003 M | 46.785 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 15 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 Einreichungen | 31. Juli 2018 | — | Erste Einreichung | — | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 2. April 2018 | — | Erste Einreichung | Passive Anlage | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 Einreichungen | 16. August 2016 | — | Erste Einreichung | — | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 Einreichungen | 23. Oktober 2012 | — | Erste Einreichung | M&A / Verkauf | SEC |
| Julian C. Baker, Felix J. Baker ×4 Einreichungen | 13. Oktober 2011 | — | Erste Einreichung | — | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 Einreichungen | 20. August 2007 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 7. Dezember 2005 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 7. Dezember 2005 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 7. Dezember 2005 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 13. Oktober 2005 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 26. Februar 2004 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 25. Februar 2004 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter, Nicht offengelegter meldender Beteiligter | 24. Februar 2004 | — | Erste Einreichung | — | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 Einreichungen | 31. Oktober 2003 | — | Erste Einreichung | — | SEC |
| William W. Featheringill | 14. Februar 2002 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 53 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,65% | 1.023.838 SH | 8. August 2026 | Täglich |
| BBP · ETFis Series Trust I | 1,93% | 125.015 NS | 30. April 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 1,26% | 1.682 NS | 30. April 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,67% | 381.305 NS | 30. April 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,54% | 612.341 NS | 30. April 2026 | N-PORT |
| CALF · Pacer Funds Trust | 0,41% | 1.556.494 NS | 30. April 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,28% | 364.624 NS | 30. April 2026 | N-PORT |
| BFOR · ALPS ETF Trust | 0,25% | 59.894 NS | 31. Mai 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,24% | 72.535 SH | 8. August 2026 | Täglich |
| GSSC · Goldman Sachs ETF Trust | 0,19% | 213.133 NS | 31. Mai 2026 | N-PORT |
| SMLF · iShares Trust | 0,17% | 758.958 SH | 8. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,16% | 13.830 SH | 8. August 2026 | Täglich |
| IBB · iShares Trust | 0,15% | 1.580.105 SH | 8. August 2026 | Täglich |
| ESSC · Strategy Shares | 0,15% | 4.183 NS | 30. April 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,14% | 249.665 SH | 8. August 2026 | Täglich |
| IWO · iShares Trust | 0,13% | 2.097.061 SH | 8. August 2026 | Täglich |
| BIB · ProShares Trust | 0,11% | 9.271 NS | 31. Mai 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,11% | 57.134 NS | 30. April 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,10% | 81.871 NS | 30. April 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 1.339.774 SH | 8. August 2026 | Täglich |
| ISCG · iShares Trust | 0,07% | 73.787 SH | 8. August 2026 | Täglich |
| IWM · iShares Trust | 0,07% | 5.925.076 SH | 8. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,07% | 206.325 SH | 8. August 2026 | Täglich |
| RSSL · Global X Funds | 0,06% | 97.958 NS | 30. April 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 806.097 NS | 30. April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,05% | 10.652 NS | 31. Mai 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,05% | 1.154.262 NS | 31. Mai 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,04% | 1.696.014 SH | 8. August 2026 | Täglich |
| ISCB · iShares Trust | 0,03% | 10.494 SH | 8. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 96.151 NS | 30. April 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.837.341 SH | 8. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,03% | 624.412 SH | 8. August 2026 | Täglich |
| UWM · ProShares Trust | 0,03% | 8.331 NS | 31. Mai 2026 | N-PORT |
| URTY · ProShares Trust | 0,02% | 8.425 NS | 31. Mai 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2.922.024 SH | 8. August 2026 | Täglich |
| WSML · iShares Trust | 0,02% | 11.689 SH | 8. August 2026 | Täglich |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 9.529 NS | 31. Mai 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 212 NS | 31. Mai 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 80.493 NS | 31. Mai 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 74.317 NS | 30. April 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 72.218 SH | 8. August 2026 | Täglich |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,00% | 937 NS | 31. Mai 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 336.352 SH | 8. August 2026 | Täglich |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 141.645 NS | 31. Mai 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 6.314 NS | 30. April 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 34.873 NS | 30. April 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,00% | 8.956 NS | 30. April 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0,00% | 129 NS | 31. Mai 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 3.019 NS | 30. April 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 8.070.274 SH | 8. August 2026 | Täglich |